2005 - New Forest Patent Application - APP
Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
Abstract
The invention relates to the use of NMDA receptor antagonists such as 1-aminocyclohexane derivatives to modify deposition of potentially toxic and fibrillogenic A.beta. peptides in amyloidopathies. Specifically, the invention relates to the ability of memantine to intervene in the processing of APP and decrease the levels of fibrillogenic A.beta. peptides.
Assignee Name and Adress: Forest Laboratories, Inc.
New York
NY
What is claimed is:
1. A method for decreasing the level of at least one amyloid peptide produced by a mammalian cell, said method comprising administering to said cell an 1-aminocyclohexane derivative.
2. The method of claim 1, wherein the amyloid peptide is sAPP.alpha., A.beta..sub.40 or A.beta..sub.42.
3. The method of claim 1, wherein the amyloid peptide is A.beta..sub.40.
4. The method of claim 1, wherein the cell is a neural cell.
============================
12. A method for modifying a deposition of a fibrillogenic .beta.-amyloid (A.beta.) peptide in a mammal comprising administering to said mammal an 1-aminocyclohexane derivative in amounts effective for this purpose.
13. The method of claim 12, wherein the 1-aminocyclohexane derivative is administered in amounts, which are in the range 0.1-150 .mu.M.
14. The method of claim 12, wherein the 1-aminocyclohexane derivative is administered in amounts, which are in the range 1-25 .mu.M.
15. The method of claim 12, wherein the 1-aminocyclohexane derivative is administered in amounts, which are in the range 1-4 .mu.M.
16. The method of claim 12, wherein the mammal is a mouse.
17. The method of claim 12, wherein the mammal is a human.
============================
I think the above suggests that Forest thinks that
Memantine can reduce Abeta 40 and Abeta 42
in Humans.
appft1.uspto.gov
John |
